Paris (France), 13 November 2009
Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.
Paris (France), 29 October 2009
Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia
Dysport® represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place.
Dysport® represents the first new botulinum toxin type A treatment option in eight years to reach the U.S. market place.
Paris (France), 29 October 2009
Ipsen’s first nine months of 2009 sales and update of Group financial objectives
• Strong third quarter: drug sales up 9.4% at constant currency – Dynamic Specialty care franchise: 16.7% sales growth at constant currency • First nine months drug sales up 7.1% year-on-year at constant currency • Group financial objectives updated
• Strong third quarter: drug sales up 9.4% at constant currency – Dynamic Specialty care franchise: 16.7% sales growth at constant currency • First nine months drug sales up 7.1% year-on-year at constant currency • Group financial objectives updated
